• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Michael Posternak, MD.

Michael Posternak, MD.

Psychiatrist in private practice, Boston, MA.
Articles

ARTICLES

Research Update

Adjuvant Clonidine for Mania

March 8, 2023
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Michael Posternak, MD. Dr. Posternak has no financial relationships with companies related to this material.

Clonidine was a promising therapy for mania in the 1980s, but the ball got dropped. This study picks that up with a modern-day randomized-controlled design.


Read More
CLINICAL UPDATE

Trichotillomania: Diagnosis and Treatment

October 30, 2022
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has no financial relationships with companies related to this material.

Trichotillomania (TTM) is a disorder that seems to lurk in the shadows. We hear about it but rarely see it. 


Read More

Oral Zuranolone for Postpartum Depression

March 4, 2022
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
If approved, this alternative to IV brexanolone will be a more practical option for treating PPD.
Read More

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.
Read More

Psilocybin vs Escitalopram for Depression

September 10, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Psilocybin is inching its way toward FDA approval in depression, but will this trial from the New England Journal of Medicine help it along or set it back?
Read More

Pilot Study of Ketamine vs ECT for Major Depression

September 10, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The first head-to-head comparison reveals a subtle difference between these two therapies
Read More

ECT Worked: Now What?

August 3, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Your patient has recovered from depression with ECT, but their chances of going back into it are high (80%). In this article, learn 3 ways to reduce that risk.
Read More

Antipsychotic Use Associated With Increased Risk of Mortality

March 11, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The study is not without flaws, but it raises some concerns about the long term health-effects of antipsychotic augmentation.
Read More

Are SSRIs Associated With Increased Rates of Violence?

February 3, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
SSRIs are often used to reduce irritability, but questions about they can cause violence have loomed over these antidepressants since the early 1990’s. This new study, with 700,000 patients followed over 7 years, suggests they can.
Read More

Keeping Up With Trintellix

October 6, 2020
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Not satisfied with its claim to improve cognitive features of depression, Trintellix has ventured into new therapeutic arenas. Sometimes with success, sometimes with failure, we review where this novel antidepressant stands in schizophrenia, anxiety, cognitive decline, ADHD, sexual dysfunction, and binge eating disorder.
Read More
View All Articles by Michael Posternak, MD.
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.